Anemia Medicines Approved in the EU (EMA)

• 21medicines authorised in the EU (authorised now)

Each number has its full source under its own list below.

• 7Mar2025

  Rytelo

  Active substance: imetelstat

  EMEA/H/C/006105
• 9Feb2024

  Casgevy

  Active substance: Exagamglogene autotemcel

  EMEA/H/C/005763
• 24Apr2023

  Vafseo

  Active substance: vadadustat

  EMEA/H/C/005131
• 15Nov2022

  Enjaymo

  Active substance: sutimlimab

  EMEA/H/C/005776
• 9Nov2022

  Pyrukynd

  Active substance: mitapivat sulfate

  EMEA/H/C/005540
• 18Aug2021

  Evrenzo

  Active substance: roxadustat

  EMEA/H/C/004871
• 25Jun2020

  Reblozyl

  Active substance: Luspatercept

  EMEA/H/C/004444
• 1Jul2019

  Xromi

  Active substance: hydroxycarbamide

  EMEA/H/C/004837
• 18Feb2016

  Feraccru

  Active substance: ferric maltol

  EMEA/H/C/002733
• 11Mar2010

  Revolade

  Active substance: eltrombopag

  EMEA/H/C/001110
• 29Oct2009

  Eporatio

  Active substance: epoetin theta

  EMEA/H/C/001033
• 23Oct2009

  Biopoin

  Active substance: epoetin theta

  EMEA/H/C/001036
• 18Dec2007

  Silapo

  Active substance: epoetin zeta

  EMEA/H/C/000760
• 18Dec2007

  Retacrit

  Active substance: epoetin zeta

  EMEA/H/C/000872
• 28Aug2007

  Binocrit

  Active substance: epoetin alfa

  EMEA/H/C/000725

Source: European Medicines Agency, Centrally authorised human medicines (EPAR), authorised now. Retrieved 12 Nov 2026.

• Anaemia in women 15–49

• Pediatric
• Maternal
• Women's health